On May 13, 2020 Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer reported the acceptance of two poster presentations at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) ("ASCO") Virtual Annual Meeting, taking place virtually from May 29, 2020 to June 2, 2020 (Press release, Y-mAbs Therapeutics, MAY 13, 2020, View Source [SID1234557967]). The presentations were submitted by Jaume Mora, M.D., Ph.D. from SJD Barcelona Children’s Hospital:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The role of autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy. Results of 2 consecutive studies in a single referral institution
Naxitamab, a new generation anti-GD2 monoclonal antibody (mAb) for treatment of relapsed/ refractory high-risk neuroblastoma (HR-NB)
Researchers at MSK developed naxitamab, which is exclusively licensed by MSK to Y-mAbs. As a result of this licensing arrangement, MSK has institutional financial interests in the product.